Biotech stocks News; BioSante Pharmaceuticals (NASDAQ: BPAX) Announces Issuance of New LibiGel® Method of Use Patent

LINCOLNSHIRE, Ill. - November 29, 2011 (Investorideas.com newswire) - BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX) today announced the issuance of a new U.S. patent covering the �method of use� of LibiGel (testosterone gel) for treating female sexual dysfunction (FSD) and hypoactive sexual desire disorder (HSDD). The patent covers methods for treating FSD and HSDD and also includes using a metered dosage device to deliver the defined dose of the testosterone formulation in LibiGel. U.S. Patent No. 8,067,399, which issued today, will expire on December 29, 2028. The two named inventors of this new patent are a current and a former employee of BioSante.

"We are very pleased that this new LibiGel patent has issued. The patent protects the use of LibiGel in treating FSD and HSDD, and the bottle we used in our clinical work, as well as in the intended commercial product, and extends our patent protection to the end of 2028,� said Stephen M. Simes, BioSante president and CEO. �Our objective has been to continue to strengthen our intellectual property covering LibiGel and this patent is a major achievement in that direction."
About LibiGel®
LibiGel is a testosterone gel in Phase III clinical development for the treatment of women who suffer from female sexual dysfunction (FSD), specifically hypoactive sexual desire disorder (HSDD). The completed Phase III efficacy trials are double-blind, placebo-controlled trials that enrolled over 500 surgically menopausal women each for six-months of therapy, approximately half of whom were taking concomitant estrogen therapy and half of whom took no concomitant estrogen therapy. The completed efficacy trials were conducted according to an FDA-agreed special protocol assessment (SPA) agreement. LibiGel is absorbed quickly through the skin after applying a once-daily pea-sized topical application on the upper arm that delivers testosterone to the bloodstream evenly over time.
In addition, BioSante is conducting the Phase III LibiGel safety study, a randomized, double-blind, placebo-controlled, multi-center, cardiovascular (CV) events and breast cancer study that has completed enrollment of 3,656 women and has accrued over 5,100 women-years of exposure, to date. The study will continue for a total of five years; however, BioSante will use the safety study data as part of an NDA submission after the last subject enrolled has completed 12 months of exposure to LibiGel or placebo.
The LibiGel safety study is tracking a predefined list of CV events, in agreement with the FDA, including CV death, myocardial infarction and stroke in women 50 years of age or older and suffering from at least two CV risk factors including hypertension and diabetes. The objective of the safety study is to demonstrate the relative safety of testosterone compared to placebo in the number of CV events. The incidence of breast cancer also is being tracked over the course of the study. The study represents the largest data base of the safety of testosterone in women.
Upon completion of the statistical analyses of efficacy trials and the safety study, BioSante intends to submit an NDA to the FDA, requesting approval of LibiGel for the treatment of HSDD in menopausal women. The NDA submission is targeted for the fourth quarter of 2012.
About BioSante Pharmaceuticals, Inc.
BioSante is a specialty pharmaceutical company focused on developing products for female sexual health and oncology. BioSante's lead products include LibiGel® (transdermal testosterone gel) for the treatment of female sexual dysfunction (FSD), specifically hypoactive sexual desire disorder (HSDD), which is in Phase III clinical development according to a U.S. Food and Drug Administration (FDA) Special Protocol Assessment (SPA). BioSante's first FDA-approved product is Elestrin™ (estradiol gel) indicated for the treatment of hot flashes associated with menopause, marketed in the U.S. by Azur Pharma, BioSante's licensee. BioSante also is developing a portfolio of cancer vaccines, four of which have been granted Orphan Drug designation, and are currently in several Phase II clinical trials. Other BioSante products are Bio-T-Gel™, a testosterone gel for male hypogonadism, for which an NDA is pending, licensed to Teva Pharmaceuticals, and an oral contraceptive in Phase II clinical development. Additional information is available online at: www.biosantepharma.com.
Forward-Looking Statements
To the extent any statements made in this news release deal with information that is not historical, these are forward-looking statements under the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, statements about BioSante's plans, objectives, expectations and intentions with respect to future operations and products, the timing of anticipated regulatory submissions and other statements identified by words such as �will,� �continue,� �could,� �believe,� �intends,� �continue,� �expects,� �anticipates,� �estimates,� �may,� other words of similar meaning, derivations of such words or the use of future dates. Forward-looking statements by their nature address matters that are, to different degrees, uncertain. Uncertainties and risks may cause BioSante's actual results to be materially different than those expressed in or implied by BioSante's forward-looking statements. For BioSante, particular uncertainties and risks include, among others, the difficulty of developing pharmaceutical products, obtaining regulatory and other approvals and achieving market acceptance; the marketing success of BioSante's licensees or sublicensees; the success of clinical testing; and BioSante's need for and ability to obtain additional financing. More detailed information on these and additional factors that could affect BioSante's actual results are described in BioSante's filings with the Securities and Exchange Commission, including its most recent annual report on Form 10-K and subsequent quarterly report on Form 10-Q. All forward-looking statements in this news release speak only as of the date of this news release. BioSante undertakes no obligation to update or revise any forward-looking statement, whether as a result of new information, future events or otherwise.
Contact:
For Investors:
The Trout Group LLC
Tricia Swanson
(646) 378-2953
tswanson@troutgroup.com
or
For Media:
Harris D. McKinney, Inc.
Alan Zachary
312-506-5220
azachary@harrisdmckinney.com
BioSante Pharmaceuticals, Inc: (NASDAQ: BPAX) is a featured showcase biotech/pharma stock on Investorideas.com
Request news, updates and trading alerts on BPAX and other showcase stocks http://www.investorideas.com/Resources/Newsletter.asp
Research more biotech stocks at the Biotech stocks Directory: http://www.investorideas.com/BIS/Stock_List.asp
About InvestorIdeas.com:
InvestorIdeas.com is a leading global investor and industry research resource portal specialized in sector investing, covering leading industry sectors including biotech and pharma stocks.
Disclaimer: The following news/content is paid for as part of the BPAX showcase program (two thousand per month) Investorideas.com is a third party publisher of news and research Our sites do not make recommendations, but offer information portals to research news, articles, stock lists and recent research. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. This site is currently compensated by featured companies, news submissions and online advertising.
Investorideas.com Disclaimer: http://www.investorideas.com/About/Disclaimer.asp  
Investorideas.com Disclosure: http://www.investorideas.com/About/News/Clientspecifics.asp  
Source: Investorideas.com, BioSante, Investorideas.com
800 665 0411 cvanzant@investorideas.com

China Stocks News; CDII (NasdaqGM:CDII) VP Richard Galterio discusses New Business ventures and Global opportunities

Deerfield Beach, Florida - November 28, 2011 (Investorideas.com Newswire) � CDII (NASDAQ:CDII) discusses state of business and global operations with Richard Galterio, VP of Investor Relations.

Headquartered in Deerfield Beach, Florida, China Direct Industries acquires controlling interests of Chinese business entities. We operate two primary business segments: Magnesium and Basic Materials. We are committed to improving the quality and performance of each subsidiary by providing an array of resources to augment their efficiency and growth. These resources include management advice, investment capital, business development services, strategic planning, internal control, macroeconomic industry analysis, and financial management. Through this ownership control, we provide resources, enabling these subsidiaries to successfully expand their operations.
In addition, we provide consulting services to Chinese entities seeking to compete in a global economy. These services include strategic planning, business development, investment and financing assistance, M&A planning and analysis, modeling and valuation analysis, financial management, SEC report filings and management, SOX 404 compliance, and investor and public relations services.
With offices in the United States and China, China Direct Industries is comprised of both Chinese and American business professionals eager to develop creative solutions to access the growing Chinese economy. Employing a multicultural team which has been operating successfully within the landscape since 2001, our organization presents a series of advantages critical to the success of Chinese entities.
About China Direct Industries
IncChina Direct Industries, Inc. (NASDAQ:CDII), is a U.S. based company that sources, produces and distributes industrial commodities in China and the Americas and provides business and financial consulting services. Headquartered in Deerfield Beach, Florida with corporate offices in Shanghai, China Direct Industries' unique infrastructure provides a platform to expand business opportunities globally while effectively and efficiently accessing the U.S. capital markets.
For more information about China Direct Industries, please visit http://www.cdii.net.
Contact Information:
China Direct Industries, Inc.
Richard Galterio or Lillian Wong
Investor Relations
Phone: 1-877-China-57
Email: richard.galterio@cdii.net
lillian.wong@cdii.net

China Direct Industries, Inc. (NasdaqGM:CDII) is a featured stock on Investorideas.com
Visit the company profile

Disclosure/ disclaimer: Our sites do not make recommendations, but offer information portals to research news, articles, stock lists and recent research. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All information published is from public filings , news , SEC filings and or company comments and quotes .China Direct Industries, Inc.(NasdaqGM: CDII ) One month online marketing paid for by third party Pearl Group; twelve thousand five hundred, to include CFA Commentary, email distribution with other Investorideas.com partners and network of online media which are also compensated as part of this overall marketing (please read their disclosures)

Friday's NASDAQ Winners: POZN, AMCF, WWIN, SPRD

POINT ROBERTS - November 28, 2011 - www.InvestorIdeas.com, a global investor research portal for independent investors, reports on top percentage gainers on the NASDAQ for Friday November 25th. NASDAQ closed with a loss of 18.57 (-0.75%) to 2,441.51. In Monday morning markets, US stocks are up sharply following Black Friday retail results.

POZEN Inc. (NASDAQ:POZN) was the top percentage winner and soared 1.12 (44.80%) to end at $3.62 after the company's news it entered into an accord with Canada's CPPIB Credit Investments (CII) to sell the company's right to receive future royalty payments arising from US sales of MT 400, including migraine drug Treximet, (sumatriptan/naproxen sodium) which incorporates the US company's MT 400 technology.
Andatee China Marine Fuel Services Corporation (NASDAQ:AMCF) surged 0.39 (11.34%) to close at $3.83 after Andatee China Marine said its chief executive aims to acquire all of the outstanding shares of Andatee that he doesn't already own in a tender offer that values the company at roughly $41.3 million.
Winner Medical Group, Inc (NASDAQ:WWIN) increased by 0.23 (7.21%) to finish a t $3.42. The company announced that it will release financial results for its fourth quarter and fiscal 2011 on Wednesday, November 30, 2011, before the market opens.
Spreadtrum Communications, Inc (ADR) (NASDAQ:SPRD) also jumped 1.58 (6.82%) to end at $24.75. Spreadtrum Communications, Inc. is a fabless semiconductor company that designs, develops and markets baseband processor, radio frequency (RF) transceiver and turnkey solutions for the wireless communications and mobile television market.
About InvestorIdeas.com:
InvestorIdeas.com is a leader in investor stock research by sector. Sectors we cover include; cleantech and renewable energy stocks, biotech stocks, mining and gold stocks, energy stocks, water, tech, defense stocks, nanotech, agriculture and gaming.
Follow Investorideas.com on Twitter http://twitter.com/#!/Investorideas
Follow Investorideas.com on Facebook http://www.facebook.com/Investorideas
Investor Research Tools;
Get Free investor news and stock alerts
Sign Up: http://www.investorideas.com/Resources/Newsletter.asp
Join Investor Ideas Get 13 of the best stock directories online;
Research oil and gas stocks, gold stocks, water stocks, renewable energy stocks (over 1300 green stocks in directory) and more
Join: http://www.investorideas.com/membership/
Disclaimer: Our sites do not make recommendations. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. We attempt to research thoroughly, but we offer no guarantees as to the accuracy of information presented. All Information relating to featured companies is sourced from public documents and/ or the company and is not the opinion of our web sites. This site is currently compensated by featured companies, news submissions and online advertising . www.InvestorIdeas.com/About/Disclaimer.asp
800-665-0411
Source - www.Investorideas.com

TSX Stocks to Watch; Friday's Trading Leaders: (TSX: WED), (TSX: SU), (TSX: RY), (TSX: MFC)

November 28, 2011 - Investorideas.com, a leader in sector research for independent investors issues a trading alert for TSX trading leaders for November 25, 2011. The Standard & Poor's/TSX Composite Index ended lower by 23.26 (-0.20%) to close the day at 11,462.06.

The Westaim Corporation (TSX:WED) was the most active stock on the TSX Friday and ended higher by 0.020 (3.70%) to C$0.560 with more than 7.38 million shares exchanged hands, compared to its average volume of 609K shares. Over the past year, the stock has been trading within a narrow range of $0.43-$0.62. The company has market capitalization of $324.99 million.
Suncor Energy Inc. (TSX:SU) fell 0.61 (-2.12%) to close at C$28.14 on over 3.50 million shares, compared to its 30-day average volume of 5.15 million shares. Suncor Energy explores for, acquires, develops, produces and markets crude oil and natural gas in Canada and internationally, and it transports and refines crude oil and market petroleum and petrochemical products primarily in Canada.
Royal Bank of Canada (TSX:RY) lost 0.50 (-1.14%) to end at C$43.40 on over 2.81 million shares, compared to its average volume of 3.45 million shares after hitting a new 52-week low of $43.30 earlier in the session. Royal Bank of Canada (RBC) is a diversified financial services company. RBC provides personal and commercial banking, wealth management services, insurance, corporate and investment banking and transaction processing services on a global basis.
Manulife Financial Corp. (TSX:MFC) shares gained 0.07 (0.65%) to close the day at C$10.84 on over 2.62 million shares. For Manulife Financial, the present is Canada and the United States, but the future will increasingly be Southeast Asia, where its insurance business is growing by 30 percent a year with the potential to improve, a senior executive said on Wednesday.
About InvestorIdeas.com: Big Ideas for small cap Investors
InvestorIdeas.com is a leader in investor stock research by sector. Sectors we cover include; cleantech and renewable energy stocks, biotech stocks, mining and gold stocks, energy stocks, water, tech, defense stocks, nanotech, agriculture and gaming.
Sign up for the free investor news and stock alerts http://www.investorideas.com/Resources/Newsletter.asp
Join Investor Ideas - Become a Member
Investorideas.com Members currently have 24/7 online access to the exclusive subscriber-only 13 stock directories in leading sectors including nanotech, renewable energy, water and energy stocks. Get stock alerts and hot news!
Visit the Investor Ideas membership page to learn more at: http://www.investorideas.com/membership/
Follow Investorideas.com on Twitter http://twitter.com/#!/Investorideas
Follow Investorideas.com on Facebook http://www.facebook.com/Investorideas
Disclaimer: Our sites do not make recommendations. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. We attempt to research thoroughly, but we offer no guarantees as to the accuracy of information presented. All Information relating to featured companies is sourced from public documents and/ or the company and is not the opinion of our web sites. This site is currently compensated by featured companies, news submissions and online advertising .
www.InvestorIdeas.com/About/Disclaimer.asp
BC Residents and Investor Disclaimer : Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894
Source - Investorideas.com
800-665-0411

Biotech Investor Alert for (OTC: AEMD), (Nasdaq:VRUS), (VRTX); Hepatitis C Virus (HCV) Treatments

POINT ROBERTS - November 28, 2011 - www.InvestorIdeas.com issues a biotech investor alert for Pharmasset, Inc. (Nasdaq:VRUS), Vertex Pharmaceuticals (VRTX) and Aethlon Medical, Inc. (OTCBB: AEMD), three stocks involved in the treatment of Hepatitis C Virus (HCV).

Over 170 million people worldwide are chronically infected with Hepatitis C. The sector made headlines earlier this week as Pharmasset, Inc. (Nasdaq:VRUS), traded up over 84% on acquisition news.
Gilead Sciences, Inc. (Nasdaq:GILD) and Pharmasset, Inc. (Nasdaq:VRUS) reported the companies have signed a definitive agreement under which Gilead will acquire Pharmasset for $137 per share in cash.
Pharmasset (Nasdaq:VRUS) has three clinical-stage product candidates for the treatment of chronic hepatitis C virus (HCV) advancing in trials in various populations. The company's lead product candidate, PSI-7977, an unpartnered uracil nucleotide analog, has recently been advanced into two Phase 3 studies in genotype 2 and 3 patients. Both studies will utilize 12 weeks of treatment with PSI-7977 in combination with ribavirin. One study will compare this all-oral regimen against 24 weeks of the standard-of-care pegylated interferon/ribavirin in treatment-naïve patients, and the second study will compare the all-oral regimen to placebo in interferon-intolerant/ineligible patients. A third Phase 3 study in genotype 1 patients will be initiated in the second half of 2012, the design of which is dependent on the outcome of Phase 2 studies which are evaluating PSI-7977 in various combinations in genotype 1-infected patients. If successful, this strategy could lead to an initial U.S. regulatory approval of PSI-7977 in 2014. PSI-938, an unpartnered guanosine nucleotide analog, is being tested in a Phase 2b interferon-free trial as monotherapy and in combination with PSI-7977 in subjects with HCV of all viral genotypes. Mericitabine (RG7128), a cytidine nucleoside analog, is partnered with Roche and is being evaluated in three Phase 2b trials. Roche is responsible for all aspects of the development of mericitabine.
Gilead's research and development portfolio includes seven unique molecules in various stages of clinical development for the treatment of HCV.
James A. Joyce, Chairman and CEO of Aethlon Medical, Inc. (OTCBB: AEMD) recently updated shareholders on November 16 th, "Our Hemopurifier® has demonstrated broad-spectrum capabilities against viral pathogens, including HCV, the human immunodeficiency virus (HIV), and a variety of tested bioterror and pandemic threats. Specific to treating HCV, we previously conducted studies that demonstrated the safe administration of our Hemopurifier® in HCV-infected dialysis patients whose average viral load reductions exceeded 50% during each four-hour treatment. These results were obtained in the absence of any drug therapy."
Full news : http://finance.yahoo.com/news/Aethlon-Medical-Releases-prnews-4279719933.html?x=0&l=
Vertex Pharmaceuticals Inc (VRTX ) announced earlier in November its interim results from ZENITH, an ongoing Phase 2 study designed to assess the safety, tolerability and efficacy of multiple 12- and 24-week response-guided treatment regimens with VX-222 (100mg or 400mg), its lead polymerase inhibitor in development, in combination with INCIVEK™ (telaprevir ) tablets, pegylated-interferon and ribavirin in people with genotype 1 chronic hepatitis C who were new to treatment. On the basis of the results announced today and previously announced data from other treatment arms of the ZENITH study, Vertex intends to start a Phase 3 study to evaluate a total treatment duration of 12 weeks with this four-drug regimen in treatment naïve and relapser patients with genotype 1 chronic hepatitis C.
More about Aethlon Medical (OTCBB: AEMD)
The Aethlon Medical mission is to create innovative medical devices that address unmet medical needs in cancer, infectious disease, and other life-threatening conditions. Our Aethlon ADAPT™ System is a revenue-stage technology platform that provides the basis for a new class of therapeutics that target the selective removal of disease enabling particles from the entire circulatory system. The Aethlon ADAPT™ product pipeline includes the Aethlon Hemopurifier® to address infectious disease and cancer; HER2osome™ to target HER2+ breast cancer, and a medical device being developed under a contract with the Defense Advanced Research Projects Agency (DARPA) that would reduce the incidence of sepsis in combat-injured soldiers and civilians. For more information, please visit www.aethlonmedical.com.
Visit the AEMD showcase page on Investorideas.com
http://www.investorideas.com/CO/AEMD
Get biotech news and stock alerts
http://www.investorideas.com/Resources/Newsletter.asp
Research more biotech stocks at the Biotech stocks Directory: http://www.investorideas.com/BIS/Stock_List.asp
About InvestorIdeas.com:
InvestorIdeas.com is a leader in investor stock research by sector. Sectors we cover include; cleantech and renewable energy stocks, biotech stocks, mining and gold stocks, energy stocks, water, tech, defense stocks, nanotech, agriculture and gaming.
Follow Investorideas.com on Twitter http://twitter.com/#!/Investorideas
Follow Investorideas.com on Facebook http://www.facebook.com/Investorideas
Disclaimer/ Disclosure : The Investorideas.com is a third party publisher of news and research Our sites do not make recommendations, but offer information portals to research news, articles, stock lists and recent research. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. This site is currently compensated by featured companies, news submissions and online advertising. AETHLON MEDICAL INC (OTC BB: AEMD) Showcase biotech, biodefense and defense stock on Investorideas.com ($one thousand five hundred per month, $five thousand per month in 144 stock) Effective March 15, 2011      
BC Residents and Investor Disclaimer: Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894
800-665-0411
Source - www.Investorideas.com

Hepatitis C Virus (HCV) Biotech and Pharma Stock News: (OTC: AEMD), (Nasdaq:VRUS), (VRTX)

POINT ROBERTS, November 25, 2011 - www.InvestorIdeas.com, a global investor research portal for independent investors, issues a biotech/pharma investor snapshot for stocks involved in the treatment of Hepatitis C Virus (HCV). Over 170 million people worldwide are chronically infected with Hepatitis C. The sector made headlines earlier this week as Pharmasset, Inc. (Nasdaq:VRUS), traded up over 84% on acquisition news.

Gilead Sciences, Inc. (Nasdaq:GILD) and Pharmasset, Inc. (Nasdaq:VRUS) reported the companies have signed a definitive agreement under which Gilead will acquire Pharmasset for $137 per share in cash.
What does this mean for the sector? Are there other potential acquisitions? Some say this acquisition makes Vertex Pharmaceuticals Inc (VRTX) look relatively cheap.
Pharmasset (Nasdaq:VRUS) has three clinical-stage product candidates for the treatment of chronic hepatitis C virus (HCV) advancing in trials in various populations. The company's lead product candidate, PSI-7977, an unpartnered uracil nucleotide analog, has recently been advanced into two Phase 3 studies in genotype 2 and 3 patients. Both studies will utilize 12 weeks of treatment with PSI-7977 in combination with ribavirin. One study will compare this all-oral regimen against 24 weeks of the standard-of-care pegylated interferon/ribavirin in treatment-naïve patients, and the second study will compare the all-oral regimen to placebo in interferon-intolerant/ineligible patients. A third Phase 3 study in genotype 1 patients will be initiated in the second half of 2012, the design of which is dependent on the outcome of Phase 2 studies which are evaluating PSI-7977 in various combinations in genotype 1-infected patients. If successful, this strategy could lead to an initial U.S. regulatory approval of PSI-7977 in 2014. PSI-938, an unpartnered guanosine nucleotide analog, is being tested in a Phase 2b interferon-free trial as monotherapy and in combination with PSI-7977 in subjects with HCV of all viral genotypes. Mericitabine (RG7128), a cytidine nucleoside analog, is partnered with Roche and is being evaluated in three Phase 2b trials. Roche is responsible for all aspects of the development of mericitabine.
Gilead's research and development portfolio includes seven unique molecules in various stages of clinical development for the treatment of HCV.
James A. Joyce, Chairman and CEO of Aethlon Medical, Inc. (OTCBB: AEMD) recently updated shareholders on November 16 th, "Our Hemopurifier® has demonstrated broad-spectrum capabilities against viral pathogens, including HCV, the human immunodeficiency virus (HIV), and a variety of tested bioterror and pandemic threats. Specific to treating HCV, we previously conducted studies that demonstrated the safe administration of our Hemopurifier® in HCV-infected dialysis patients whose average viral load reductions exceeded 50% during each four-hour treatment. These results were obtained in the absence of any drug therapy."
Full news: http://finance.yahoo.com/news/Aethlon-Medical-Releases-prnews-4279719933.html?x=0&l=
Vertex Pharmaceuticals Inc (VRTX) announced earlier in November its interim results from ZENITH, an ongoing Phase 2 study designed to assess the safety, tolerability and efficacy of multiple 12- and 24-week response-guided treatment regimens with VX-222 (100mg or 400mg), its lead polymerase inhibitor in development, in combination with INCIVEK™ (telaprevir) tablets, pegylated-interferon and ribavirin in people with genotype 1 chronic hepatitis C who were new to treatment. On the basis of the results announced today and previously announced data from other treatment arms of the ZENITH study, Vertex intends to start a Phase 3 study to evaluate a total treatment duration of 12 weeks with this four-drug regimen in treatment naïve and relapser patients with genotype 1 chronic hepatitis C.
More about Aethlon Medical (OTCBB: AEMD)
The Aethlon Medical mission is to create innovative medical devices that address unmet medical needs in cancer, infectious disease, and other life-threatening conditions. Our Aethlon ADAPT™ System is a revenue-stage technology platform that provides the basis for a new class of therapeutics that target the selective removal of disease enabling particles from the entire circulatory system. The Aethlon ADAPT™ product pipeline includes the Aethlon Hemopurifier® to address infectious disease and cancer; HER2osome™ to target HER2+ breast cancer, and a medical device being developed under a contract with the Defense Advanced Research Projects Agency (DARPA) that would reduce the incidence of sepsis in combat-injured soldiers and civilians. For more information, please visit www.aethlonmedical.com.
Visit the AEMD showcase page on Investorideas.com
http://www.investorideas.com/CO/AEMD
Get biotech news and stock alerts
http://www.investorideas.com/Resources/Newsletter.asp
Research more biotech stocks at the Biotech stocks Directory: http://www.investorideas.com/BIS/Stock_List.asp
About InvestorIdeas.com:
InvestorIdeas.com is a leader in investor stock research by sector. Sectors we cover include; cleantech and renewable energy stocks, biotech stocks, mining and gold stocks, energy stocks, water, tech, defense stocks, nanotech, agriculture and gaming.
Follow Investorideas.com on Twitter http://twitter.com/#!/Investorideas
Follow Investorideas.com on Facebook http://www.facebook.com/Investorideas
Disclaimer/ Disclosure : The Investorideas.com is a third party publisher of news and research Our sites do not make recommendations, but offer information portals to research news, articles, stock lists and recent research. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. This site is currently compensated by featured companies, news submissions and online advertising. AETHLON MEDICAL INC (OTC BB: AEMD) Showcase biotech, biodefense and defense stock on Investorideas.com ($one thousand five hundred per month, $five thousand per month in 144 stock) Effective March 15, 2011       
BC Residents and Investor Disclaimer: Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894
800-665-0411
Source - www.Investorideas.com

TSX Stocks to Watch; Thursday's Trading Leaders: (TSX: AAB), (TSX: NRG), (TSX: MNB), (TSX: CEE)

November 25, 2011 - Investorideas.com, a leader in sector research for independent investors issues a trading alert for TSX trading leaders for November 24, 2011. The Standard & Poor's/TSX Composite Index ended lower by 86.39 (-0.75%) to close the day at 11,485.32.

Aberdeen International Inc. (TSX: AAB) was the most active stock on the TSX and ended higher by 0.020 (3.23%) to close at C$0.64, rebounding from its recent lows. Recently, the company announced that the value of its investment portfolio as at October 31, 2011, the end of its 2012 third fiscal quarter, was approximately $100.1 million including a cash balance of $7.4 million.
Alter Nrg Corp. (TSX: NRG) soared 0.180 (24.00%) to end at C$0.93 on over 1.29 million shares, compared to its 30-day average volume of 60K shares. Alter Nrg Corp. announced that it has received notification of a proposed agreement (the agreement) to be finalized by the middle of December for Alter to be the selected provider for the engineering, fabrication and construction of a plasma gasifier for installation at the proposed Tees Valley Renewable Energy Facility in Northeast England.
Mirabela Nickel Limited (TSX:MNB) added 0.04 (2.65%) to finish at C$1.55 on over 1.27 million shares, compared to its average volume of 623K shares after the company announced Record sales of nickel in concentrate for the quarter of 4,228 tonnes. A 15% decrease in unit cash costs for the quarter to US$6.71/lb (Q2 2011: US$7.85/lb) and expected to continue to decrease further during the fourth quarter.
Centamin Egypt Limited (TSX: CEE) shares fell 0.05 (-3.55%) to close the day at C$.36 on over 1.12 million shares. Centamin Egypt Limited (Centamin) is a mineral exploration development and mining company. Centamin is engaged in the exploration for precious and base metals, production of gold and ongoing development at the Sukari project.
About InvestorIdeas.com: Big Ideas for small cap Investors
InvestorIdeas.com is a leader in investor stock research by sector. Sectors we cover include; cleantech and renewable energy stocks, biotech stocks, mining and gold stocks, energy stocks, water, tech, defense stocks, nanotech, agriculture and gaming.
Sign up for the free investor news and stock alerts http://www.investorideas.com/Resources/Newsletter.asp
Join Investor Ideas - Become a Member
Investorideas.com Members currently have 24/7 online access to the exclusive subscriber-only 13 stock directories in leading sectors including nanotech, renewable energy, water and energy stocks. Get stock alerts and hot news!
Visit the Investor Ideas membership page to learn more at: http://www.investorideas.com/membership/
Follow Investorideas.com on Twitter http://twitter.com/#!/Investorideas
Follow Investorideas.com on Facebook http://www.facebook.com/Investorideas
Disclaimer: Our sites do not make recommendations. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. We attempt to research thoroughly, but we offer no guarantees as to the accuracy of information presented. All Information relating to featured companies is sourced from public documents and/ or the company and is not the opinion of our web sites. This site is currently compensated by featured companies, news submissions and online advertising .
www.InvestorIdeas.com/About/Disclaimer.asp
BC Residents and Investor Disclaimer : Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894
Source - Investorideas.com
800-665-0411

Wednesday's NASDAQ Top Gainers: PNBC, TSPT, AMCN, OPTT

POINT ROBERTS - November 24, 2011 - www.InvestorIdeas.com, a global investor research portal for independent investors, reports on top percentage gainers on the NASDAQ for Wednesday November 23rd. NASDAQ closed with a sharp loss of 61.20 (-2.43%) to 2,460.08.

Princeton National Bancorp, Inc. (NASDAQ:PNBC) was the top percentage winner soaring 0.32 (17.77%) to end at $2.12, extending its weekly gains to over 110% on heavy volume. The stock has a 52-week range of $0.86-$7.32. The company has market capitalization of $7.07 million.
Transcept Pharmaceuticals, Inc. (NASDAQ:TSPT) surged 0.73 (11.04%) to finish at $7.34, after the company said that U.S. Food and Drug Administration (FDA) has approved Intermezzo (zolpidem tartrate sublingual tablet) C-IV for use as needed for the treatment of insomnia when a middle-of-the-night awakening is followed by difficulty returning to sleep.
AirMedia Group Inc. (ADR) (NASDAQ:AMCN) increased by 0.28 (10.41%) to end at $2.97 after the advertisement business in China continues to be a strong growth story. Chinese advertisers spent approximately $33 billion on advertising last year, and that number is expected to nearly double by 2014.
Ocean Power Technologies, Inc. (NASDAQ:OPTT) jumped 0.28 (10.04%) to close at $3.07, rebounding from its recent low. The stock has a 52-week range of $2.33-$6.80. The company has market capitalization of $31.91 million.
About InvestorIdeas.com:
InvestorIdeas.com is a leader in investor stock research by sector. Sectors we cover include; cleantech and renewable energy stocks, biotech stocks, mining and gold stocks, energy stocks, water, tech, defense stocks, nanotech, agriculture and gaming.
Follow Investorideas.com on Twitter http://twitter.com/#!/Investorideas
Follow Investorideas.com on Facebook http://www.facebook.com/Investorideas
Investor Research Tools;
Get Free investor news and stock alerts
Sign Up: http://www.investorideas.com/Resources/Newsletter.asp
Join Investor Ideas Get 13 of the best stock directories online;
Research oil and gas stocks, gold stocks, water stocks, renewable energy stocks (over 1300 green stocks in directory) and more
Join: http://www.investorideas.com/membership/
Disclaimer: Our sites do not make recommendations. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. We attempt to research thoroughly, but we offer no guarantees as to the accuracy of information presented. All Information relating to featured companies is sourced from public documents and/ or the company and is not the opinion of our web sites. This site is currently compensated by featured companies, news submissions and online advertising . www.InvestorIdeas.com/About/Disclaimer.asp
800-665-0411
Source - www.Investorideas.com

TSX Stocks to Watch; Wednesday’s Trading Leaders:  (TSX: AAA), (TSX: LSG), (TSX: LUN), (TSX: ASR)

Mining Stocks Most Active for TSX Investors- But Markets Fall 
November 24, 2011 - Investorideas.com, a leader in sector research for independent investors issues a trading alert for TSX trading leaders for November 23, 2011. The Standard & Poor's/TSX Composite Index fell 223.48 (1.89%) to close the day at 11,571.71.

ALLANA POTASH CORP (TSX: AAA) was the most actively traded stock on the TSX and ended lower by 3.42% to C$1.13 after. Earlier this week, the company announced the results of an independent Preliminary Economic Assessment ("PEA") prepared by Ercosplan Ingenieurgesellschaft Geotechnik und Bergau ("ERCOSPLAN") on its Danakhil Potash Project in Ethiopia (the "Project").
Lake Shore Gold Corp.  (TSX: LSG) also ended lower by 0.11 (-8.05%) to close at C$1.37 on over 8.18 million shares, compared to its 30-day average volume of 4.67 million shares. Earlier this week, the company announced the completion of an initial National Instrument ("NI") 43-101 resource estimate for the Company's wholly owned Fenn-Gib property located approximately 60 km's east of Timmins, Ontario.
Lundin Mining Corporation (TSX: LUN) fell 0.13 (-3.74%) to C$3.35 on over 4.20 million shares, compared to its average volume of 5.68 million shares. Lundin Mining is a diversified Canada-based base metals mining company with operations in Portugal, Sweden, Spain and Ireland, producing copper, zinc, lead and nickel.
Alacer Gold Corp (TSX: ASR) shares added 0.18 (1.67%) to close the day at C$10.93 on over 2.85 million shares. Alacer Gold Corp. (Alacer), formerly Anatolia Minerals Development, is an intermediate gold producer. As of December 31, 2010, the Company held interests in four operating gold mines in Australia and Turkey.
About InvestorIdeas.com: Big Ideas for small cap Investors
InvestorIdeas.com is a leader in investor stock research by sector. Sectors we cover include; cleantech and renewable energy stocks, biotech stocks, mining and gold stocks, energy stocks, water, tech, defense stocks, nanotech, agriculture and gaming.

Sign up for the free investor news and stock alerts http://www.investorideas.com/Resources/Newsletter.asp

Join Investor Ideas – Become a Member
Investorideas.com Members currently have 24/7 online access to the  exclusive subscriber-only 13 stock directories in leading sectors including  nanotech, renewable energy, water and energy stocks. Get stock alerts and hot news! 
Visit the Investor Ideas membership page to learn more at: http://www.investorideas.com/membership/

Follow Investorideas.com on Twitter http://twitter.com/#!/Investorideas
Follow Investorideas.com on Facebook   http://www.facebook.com/Investorideas

Disclaimer: Our sites do not make recommendations. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. We attempt to research thoroughly, but we offer no guarantees as to the accuracy of information presented. All Information relating to featured companies is sourced from public documents and/ or the company and is not the opinion of our web sites. This site is currently compensated by featured companies, news submissions and online advertising.

www.InvestorIdeas.com/About/Disclaimer.asp
BC Residents and Investor Disclaimer : Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894

Source – Investorideas.com
800-665-0411

Tuesday's NASDAQ Top Percentage Winners: WCAA, FMCN, BRCD, CSIQ

POINT ROBERTS - November 23, 2011 - www.InvestorIdeas.com, a global investor research portal for independent investors, reports on top percentage gainers on the NASDAQ for Tuesday November 22nd. NASDAQ closed almost flat with a loss of 1.86 (-0.07%) at 2,521.28.

WCA Waste Corporation (NASDAQ:WCAA) was the biggest percentage gainer, gaining $0 .74 (18.41%) to close at $4.76. The stock has a 52-week range of $3.01-$6.27. WCA Waste Corporation (WCA Waste) is a vertically integrated, non-hazardous solid waste management company providing non-hazardous solid waste collection, transfer, processing, and disposal services in the south and central regions of the United States.
Focus Media Holding Limited (ADR) (NASDAQ:FMCN) added 2.27 (14.71%) to end at $17.70, rebounding from its recent losses as it denied a report that it had overstated the size of its advertising network.
Brocade Communications Systems, Inc. (NASDAQ:BRCD) gained 0.59 (13.17%) to finish at $5.07 after the company said that it earned 16 cents a share on revenue of $550 million in its fourth quarter. The company said it expects revenue in a range of $530 million to $550 million in its fiscal first quarter. That compares to estimates of $541 million from analysts in a Bloomberg survey.
Canadian Solar Inc. (NASDAQ:CSIQ climbed 0.28 (12.73%) to end at $2.48, rebounding from its 52-week low of $2.07. The company swung to a third-quarter net loss from a year-earlier profit on 32% higher revenue. The net loss was US$43.9 million, or $1.02 a share, compared with net income of $20.3 million, or 47 cents, in the year-earlier period. Revenue reached $499.6 million from $377.2 million.
About InvestorIdeas.com:
InvestorIdeas.com is a leader in investor stock research by sector. Sectors we cover include; cleantech and renewable energy stocks, biotech stocks, mining and gold stocks, energy stocks, water, tech, defense stocks, nanotech, agriculture and gaming.
Follow Investorideas.com on Twitter http://twitter.com/#!/Investorideas
Follow Investorideas.com on Facebook http://www.facebook.com/Investorideas
Investor Research Tools;
Get Free investor news and stock alerts
Sign Up: http://www.investorideas.com/Resources/Newsletter.asp
Join Investor Ideas Get 13 of the best stock directories online;
Research oil and gas stocks, gold stocks, water stocks, renewable energy stocks (over 1300 green stocks in directory) and more
Join: http://www.investorideas.com/membership/
Follow Investorideas.com on Twitter http://twitter.com/#!/Investorideas
Follow Investorideas.com on Facebook http://www.facebook.com/Investorideas
Disclaimer: Our sites do not make recommendations. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. We attempt to research thoroughly, but we offer no guarantees as to the accuracy of information presented. All Information relating to featured companies is sourced from public documents and/ or the company and is not the opinion of our web sites. This site is currently compensated by featured companies, news submissions and online advertising . www.InvestorIdeas.com/About/Disclaimer.asp
800-665-0411
Source - www.Investorideas.com

TSX Stocks to Watch; Tuesday's Trading Leaders: (TSX: ELR), (TSX: ORA), (TSX: K), (TSX: SU)

Mining and Energy Stocks Take the Lead in Tuesday's Trading


November 23, 2011 - Investorideas.com, a leader in sector research for independent investors issues a trading alert for TSX trading leaders for November 22, 2011. The Standard & Poor's/TSX Composite Index jumped 10.47 (0.09%) to close the day at 11,795.19, as US markets closed down.

Eastern Platinum Ltd. (TSX: ELR) was the top trader on TSX and ended lower by 0.060 (-9.84%) to close at C$0.550 after hitting a new 52-week low of $0.53 earlier in the session. Eastern Platinum is a platinum group metals producer with properties located in South Africa.
Aura Minerals Inc. (TSX: ORA) ended higher by 0.04 (3.45%) to close at C$1.20 on over 9.60 million shares, compared to its 30-day average volume of 1.06 million shares. Last week, the company announced financial and operating results for the third quarter of 2011.
Kinross Gold Corporation (TSX: K) surged 0.75 (5.83%) to end at C$13.62 on over 8.19 million shares, compared to its average volume of 10K shares. The stock also made a new 52-week high of $13.65.
Suncor Energy Inc. (TSX: SU) shares slid 0.52 (-1.68%) to close the day at C$30.42 on over 5.34 million shares on no major news. Canadian oil-and-gas giant Suncor has started sending a few people to Libya's capital for meetings as part of a post-war "re-entry plan."
About InvestorIdeas.com: Big Ideas for small cap Investors
InvestorIdeas.com is a leader in investor stock research by sector. Sectors we cover include; cleantech and renewable energy stocks, biotech stocks, mining and gold stocks, energy stocks, water, tech, defense stocks, nanotech, agriculture and gaming.
Sign up for the free investor news and stock alerts http://www.investorideas.com/Resources/Newsletter.asp
Join Investor Ideas - Become a Member
Investorideas.com Members currently have 24/7 online access to the exclusive subscriber-only 13 stock directories in leading sectors including nanotech, renewable energy, water and energy stocks. Get stock alerts and hot news!
Visit the Investor Ideas membership page to learn more at: http://www.investorideas.com/membership/
Follow Investorideas.com on Twitter http://twitter.com/#!/Investorideas
Follow Investorideas.com on Facebook http://www.facebook.com/Investorideas
Disclaimer: Our sites do not make recommendations. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. We attempt to research thoroughly, but we offer no guarantees as to the accuracy of information presented. All Information relating to featured companies is sourced from public documents and/ or the company and is not the opinion of our web sites. This site is currently compensated by featured companies, news submissions and online advertising.
www.InvestorIdeas.com/About/Disclaimer.asp
BC Residents and Investor Disclaimer: Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894
Source - Investorideas.com
800-665-0411

Frac Water Treatment : Q&A Interview with GreenHunter Water LLC (AMEX:GRH)

Point Roberts, WA - November 23, 2011 - Investorideas.com, a leader in sector research including water stocks and energy stocks issues a recent Q&A interview with GreenHunter Water LLC, a wholly owned subsidiary of GreenHunter Energy, Inc (AMEX: GRH). Jonathan D. Hoopes, President & COO discusses how their products and services will play a key role in providing water, environmental and regulatory solutions for shale producers.

Q: Investorideas.com
GreenHunter Water, LLC, your wholly owned subsidiary, recently announced a contract for the Eagle Ford Shale drilling area. Can you tell us the scope of the contract and the direct use for your technology?
A: Jonathan D. Hoopes; President & COO
This contract is a long term agreement to provide frac tanks and other equipment typically rented for hydraulic fracturing operations. Due to difficulties in obtaining equipment when it is needed, the operator desired to enter into a long term contract to secure the items that are necessary to ensure smooth logistics and operational efficiency and prevent delays in their drilling program.
Q: Investorideas.com
With increasing regulation and pressure for the oil and gas industry to deal with frac water, how do you see your company rolling out your technology?
A: Jonathan D. Hoopes; President & COO
We anticipate an increase in demand for GreenHunter Water's Total Water Management Solutions™ as the perceived and real need to reuse water increases. The technologies that we deploy have been in a development phase for many years and there are several viable technology platforms that we have identified for use with multiple drilling areas.
Q: Investorideas.com
What differentiates your technology in the marketplace?
A: Jonathan D. Hoopes; President & COO
GreenHunter Water's water treatment technology is designed to be highly adaptable. Because the oilfield is an industry with many unforeseen variables, adaptability is a key ingredient for success. For example, flowback from a single shale play can be, and often is, strikingly different from well to well and even a single producer may be faced with highly divergent needs. In cases where the water is similar, logistical needs may differ due to geography, limitations in infrastructure, labor shortages and urgent time tables.
Accordingly, GreenHunter Water uses a technology-agnostic approach to oilfield water treatment. When we provide our Frac-Cycle™ water treatment service, we do so in a consultative and collaborative approach with our clients after gaining an understanding of their specific needs and objectives.
Q: Investorideas.com
As GreenHunter Water builds out its salt water disposal and water treatment technologies, what other applications do you see moving forward?
A: Jonathan D. Hoopes; President & COO
We are working with E&P (exploration and production) companies on multiple RFPs (requests for proposals). These include improved logistics, hauling and water transfer contracts, temporary modular storage and frac tank rental agreements, RAMCAT™ (Remote Access Monitoring and Compliance Asset Tracking) cradle-to-grave tracking solutions, condensate drip gas reclamation and marketing and turnkey salt water disposal management agreements. We believe our multi-pronged approach is the right way to penetrate the market and we expect to see significant business growth in 2012.
GreenHunter Water LLC ( AMEX:GRH) is a wholly owned subsidiary of GreenHunter Energy, Inc. which provides Total Water Management Solutions(TM) in the oilfield. An understanding that there is no single solution to E&P fluids management shapes GreenHunter's technology-agnostic approach to services. In addition to licensing of and joint ventures with manufacturers of mobile water treatment systems, GreenHunter Water is expanding capacity of salt water disposal, temporary above-ground storage, hauling and fresh water logistics services - including 21st Century tracking technologies that allow Shale producers to optimize the efficiency of their water resource management and planning while complying with emerging regulations.
Linkedin.com: Water Stocks - Social network for investors following water stocks
http://www.linkedin.com/e/ez47wj-gp5ofknw-5j/vgh/3966202/
Linkedin.com Energy Stocks - Social network for investors following energy stocks
http://www.linkedin.com/groups/Energy-stocks-News-Social-Network-3799535?trk=myg_ugrp_ovr
Research water stocks with the water stocks directory:
http://www.investorideas.com/Water-Stocks/Stock_List.asp
Sign up for free investor newsletters and stock alerts at Investor Ideas
http://www.investorideas.com/Resources/Newsletter.asp
About InvestorIdeas.com:
InvestorIdeas.com is a leader in investor stock research by sector. Sectors we cover include; cleantech and renewable energy stocks, biotech stocks, mining and gold stocks, energy stocks, water, tech, defense stocks, nanotech, agriculture and gaming.
Follow Investorideas.com on Twitter http://twitter.com/#!/Investorideas
Follow Investorideas.com on Facebook http://www.facebook.com/Investorideas
Our sites do not make recommendations. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. We attempt to research thoroughly, but we offer no guarantees as to the accuracy of information presented. All Information relating to featured companies is sourced from public documents and/ or the company and is not the opinion of our web sites. This site is currently compensated by news submissions and online advertising. Compensation Disclosure and disclaimers: www.InvestorIdeas.com/About/Disclaimer.asp, http://www.investorideas.com/About/News/Clientspecifics.asp BC Residents and Investor Disclaimer : Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894
For More Information Contact:
Web Site: www.InvestorIdeas.com www.water-stocks.com
800 665 0411
Source: Water-Stocks.com, Investorideas.com

Frac Water Treatment: Water Stocks to Watch: (OTCBB:ABHD), (OTCBB:ESPH), (GRH), (OTCBB:WSCE)

Point Roberts, WA - November 22, 2011 � Investorideas.com, a leader in sector research including water stocks and energy stocks issues a snapshot of four water stocks with technologies that are being used in the energy sector for remediation of produced and or frac water.

As new rules and regulations governing the oil and gas industry are introduced , the treatment of frac water and produced water create a problem for the energy industry but a booming business opportunity for the water companies with technologies that provide solutions .
As the Wall Street Journal recently stated, "The growing volume of dirty water produced in shale-gas drilling has triggered a gold rush among water-treatment companies."
AbTech Holdings, Inc.(OTCBB: ABHD) announced last week the successful completion of field testing of its Smart Sponge® Mixed Media Contactor ("Contactor") to treat produced water at a Wyoming natural gas exploration and production site. The AbTech Contactors were designed to remove the hydrocarbons present in the produced water in order to protect and thereby substantially increase the useful life of downstream treatment equipment and technologies including a reverse osmosis system. The Smart Sponge Mixed Media Contactors removed 99.99% of the free oil and dissolved phase hydrocarbons (BTEX). Field testing and data collection was done under rigorous conditions throughout the fall of 2011.
Ecosphere Technologies, Inc (OTCBB:ESPH) announced that its majority-owned subsidiary, Ecosphere Energy Services, LLC has treated approximately 1.095 billion gallons of frac water since 2008 for major energy exploration and production companies to eliminate chemicals and preserve vital water resources.
GreenHunter Water, LLC, a wholly owned subsidiary of GreenHunter Energy, Inc. (NYSE Amex: GRH), announced earlier this month that it has secured a significant new order to provide equipment rental and services which include thirty (30) new frac storage tanks to an independent oil and gas operator active in the Eagle Ford Shale drilling region of South Texas. Delivery of the new frac tanks was completed approximately one week ago. The initial one year contract includes rental and management of multiple sized fluid tanks, including 500 BBL water storage tanks, manifolds and other services. This new customer is also exploring other business opportunities offered by GreenHunter's Total Water Management Solutions™. These include water treatment and reuse of "clean brine", RAMCAT™ remote access monitoring equipment, water hauling and commercial salt water disposal, and advanced logistics optimization.
Wescorp Energy Inc. (OTCBB:WSCE) is focused on applications for environmental remediation, metering and measurement, oil and gas field intelligence solutions, and solutions for unconventional oil and gas. The company's technology has been field tested for produced water but has frac water applications as well . H2Omaxx utilizes proprietary next generation aeration technology to clean and separate oil and solids from water. It has been proven to be safe, effective, economical and an environmentally-friendly process. Independent test results have shown the H20maxx technology will reduce the oil content in oil well produced water to less than 10 parts per million without the use of chemicals, filters or heat.
*Wall Street Journal source: http://online.wsj.com/article_email/SB10001424053111903918104576502562678793674-lMyQjAxMTAxMDEwMjExNDIyWj.html?mod=wsj_share_email
Linkedin.com: Water Stocks - Social network for investors following water stocks
http://www.linkedin.com/e/ez47wj-gp5ofknw-5j/vgh/3966202/
Linkedin.com Energy Stocks - Social network for investors following energy stocks
http://www.linkedin.com/groups/Energy-stocks-News-Social-Network-3799535?trk=myg_ugrp_ovr
Research water stocks with the water stocks directory: get a list of all the frac water treatment stocks
http://www.investorideas.com/Water-Stocks/Stock_List.asp
Visit www.water-stocks.com for more research on the sector.
Sign up for free investor newsletters and stock alerts at Investor Ideas
http://www.investorideas.com/Resources/Newsletter.asp
About InvestorIdeas.com:
InvestorIdeas.com is a leader in investor stock research by sector. Sectors we cover include; cleantech and renewable energy stocks, biotech stocks, mining and gold stocks, energy stocks, water, tech, defense stocks, nanotech, agriculture and gaming.
Follow Investorideas.com on Twitter http://twitter.com/#!/Investorideas
Follow Investorideas.com on Facebook http://www.facebook.com/Investorideas
Our sites do not make recommendations. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. We attempt to research thoroughly, but we offer no guarantees as to the accuracy of information presented. All Information relating to featured companies is sourced from public documents and/ or the company and is not the opinion of our web sites. This site is currently compensated by news submissions and online advertising. Compensation Disclosure and disclaimers: www.InvestorIdeas.com/About/Disclaimer.asp, http://www.investorideas.com/About/News/Clientspecifics.asp Disclosure : WSCE is a previous showcase company on Investorideas.com and Investorideas.com owns 100,000 shares.
BC Residents and Investor Disclaimer: Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894
For More Information Contact:
Web Site: www.InvestorIdeas.com www.water-stocks.com
800 665 0411
Source: Water-Stocks.com, Investorideas.com

Nanotechnology Stocks; mPhase (OTC.BB:XDSL) Explains Key Technology Features of Smart Surface Technology

LITTLE FALLS, NJ - November 22, 2011 (Investorideas.com Newswire) - mPhase Technologies, Inc. (OTC.BB: XDSL.OB) has developed a technology that exploits the phenomenon of electrowetting or the ability to electronically manipulate the way liquids behave when in contact with a solid or porous surface. Liquids such as water will bead up on a surface that is superhydrophobic, but can be made to move or spread out by electrowetting. The same is true for an organic liquid if the surface is superlyophobic.

mPhase is pursuing this emerging technology, which is now being actively researched at a number of universities who are publicizing their work on electrowetting, superhydrophobicity and superlyophobicity.
The technology is being used to create so-called "smart" structures on metal, ceramic, polymer surfaces and other advanced materials that can resist getting dirty, fogging up, or forming ice. They also can be used for displays, lenses and other applications.
To date mPhase has been concentrating on smart battery applications by exploiting this same electrowetting phenomenon in their Smart NanoBattery by manipulating the liquid electrolyte via a proprietary porous silicon structure shown in Figure 1.
The breakthrough has enabled a unique reserve-style battery architecture that has proven adaptable to a wide range of chemistries, with the initial development based on zinc manganese dioxide (Zn/MnO2) chemistries, similar to the typical alkaline battery used in a flashlight or TV remote control, as well as development focused on higher-energy density, lithium manganese dioxide (Li/MnO2), chemistries found in laptops, cell phones and digital cameras. Future applications that can be implemented within the same architecture include rechargeable batteries based on lithium-based chemistries.
These correlate to first launching and proving out the technology for a reserve battery, then a primary cell with the Zn/MnO2 or Li/MnO2 chemistries, and later a secondary (rechargeable) battery.
At that point, if completed the family of mPhase Batteries will be (reserve, primary and secondary) potentially serving a wide range of applications.
About mPhase Technologies, Inc.
mPhase Technologies is introducing a revolutionary Smart Surface technology enabled by breakthroughs in nanotechnology, MEMS processing and microfluidics. Our Smart Surface technology has potential applications within drug delivery systems, lab-on-a-chip analytic systems, self-cleaning systems, liquid and chemical sensor systems, and filtration systems. mPhase has pioneered its first Smart Surface enabled product, the mPhase Smart NanoBattery.
In addition to the Smart Surface technology, mPhase recently introduced its first product, the mPower Emergency Illuminator, an award-winning product designed by Porsche Design Studio and sold via the mPower website: http://www.mpowertech.com. More information about the company can be found at http://www.mPhaseTech.com.
Forward-Looking Statements
As a cautionary note to investors, certain matters discussed in this press release may be forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such matters involve risks and uncertainties that may cause actual results to differ materially, including the following: changes in economic conditions; general competitive factors; acceptance of the Company's products in the market; the Company's success in technology and product development; the Company's ability to execute its business model and strategic plans; and all the risks and related information described from time to time in the Company's SEC filings, including the financial statements and related information contained in the Company's SEC Filing. mPhase assumes no obligation to update the information in this release.
Contact:
973-256-3737
mPhase Technologies, Inc.

Visit the XDSL showcase profile at Investorideas.com
Request News and Info on XDSL
Disclosure, Disclaimer/ XDSL is a paid advertising client on Investorideas.com and our technology portals.